Screening diabetic patients for non-Alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study

Gut

Volumn 65, Issue 8, 2016, Pages 1359-1368

  Kwok, Raymond ^a   Choi, Kai Chow ^a   Wong, Grace Lai Hung ^a   Zhang, Yuying ^a   Chan, Henry Lik Yuen ^a   Luk, Andrea On Yan ^a   Shu, Sally She Ting ^a   Chan, Anthony Wing Hung ^a   Yeung, Ming Wai ^a   Chan, Juliana Chung Ngor ^a   Kong, Alice Pik Shan ^a   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED ATTENUATION PARAMETER; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE DURATION; ELASTOGRAPH; ELASTOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS MEASUREMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; BIOPSY; COMPLICATION; DEVICES; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; HONG KONG; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MASS SCREENING; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; RISK ASSESSMENT;

BIOPSY; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELASTICITY IMAGING TECHNIQUES; FEMALE; HONG KONG; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MASS SCREENING; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84930401292     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309265     Document Type: Article

References (39)

1. Wong VW, Wong GL, Yeung DK, et al. Incidence of non-Alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015;62:182-9.
2. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-Alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut 2010;59:969-74.
3. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
4. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology 2011;54:1208-16.
5. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-Alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22:788-93.
6. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-Alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
8. Wong VW, Chan HL. Transient elastography. J Gastroenterol Hepatol 2010;25:1726-31.
9. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-35.
10. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat 2012;19:244-53.
11. de Ledinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. J Hepatol 2014;60:1026-31.
12. Piwernetz K, Home PD, Snorgaard O, et al. Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: The DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med 1993;10:371-7.
13. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
14. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
15. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62.
16. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-71.
17. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
18. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, 2000.
19. Gupte P, Amarapurkar D, Agal S, et al. Non-Alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-8.
20. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-14.
21. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-Alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-5.
22. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-Alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-43.
23. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
24. Dixon JB, Bhathal PS, OBrien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
25. Wong VW, Hui AY, Tsang SW, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;24:1215-22.
26. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
27. Jacqueminet S, Lebray P, Morra R, et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 2008;6:828-31.
28. Casey SP, Kemp WW, McLean CA, et al. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol 2012;47:836-41.
29. de Ledinghen V, Vergniol J, Gonzalez C, et al. Screening for liver fibrosis by using FibroScan((R)) and FibroTest in patients with diabetes. Dig Liver Dis 2012;44:413-18.
30. Morling JR, Fallowfield JA, Guha IN, et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. J Hepatol 2014;60:384-91.
31. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-35.
32. Wong GL, Wong VW, Chim AM, et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300-5.
33. Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182-91.
34. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-602.
35. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
36. Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-Alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009;29:387-96.
37. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
38. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014;60:2008-16.
39. Hui AY, Wong VW, Chan HL, et al. Histological progression of non-Alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005;21:407-13.